Home » Stocks » ContraFect

ContraFect Corporation (CFRX)

Stock Price: $5.34 USD -0.02 (-0.37%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
After-hours: $5.20 -0.14 (-2.62%) Oct 21, 6:43 PM

Stock Price Chart

Key Info

Market Cap 148.50M
Revenue (ttm) n/a
Net Income (ttm) -40.91M
Shares Out 27.81M
EPS (ttm) -3.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $5.34
Previous Close $5.36
Change ($) -0.02
Change (%) -0.37%
Day's Open 5.39
Day's Range 5.23 - 5.46
Day's Volume 67,548
52-Week Range 2.90 - 13.40

More Stats

Market Cap 148.50M
Enterprise Value 112.60M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 27.81M
Float 24.50M
EPS (basic) -3.31
EPS (diluted) -3.12
FCF / Share -1.45
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.73M
Short Ratio 7.24
Short % of Float 7.05%
Beta 1.00
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 10.40
Revenue n/a
Operating Income -30.32M
Net Income -40.91M
Free Cash Flow -29.01M
Net Cash 35.90M
Net Cash / Share 1.29
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -42.77%
ROE -348.74%
ROIC -306.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$17.75*
(232.40% upside)
Low
12.0
Current: $5.34
High
22.0
Target: 17.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue--------
Operating Income-27.87-31.12-26.56-33.53-25.07-16.94-19.30-19.15
Net Income-12.79-37.68-15.52-28.54-25.12-30.15-23.62-19.28
Shares Outstanding8.287.615.563.352.330.900.100.10
Earnings Per Share-1.54-4.95-2.79-8.50-10.80-38.60-233.50-191.60
Operating Cash Flow-27.43-26.26-24.53-29.30-22.18-14.86-14.06-16.31
Capital Expenditures-0.02-0.13--0.11-0.010.040.01-0.06
Free Cash Flow-27.45-26.39-24.53-29.41-22.19-14.83-14.04-16.37
Cash & Equivalents24.1830.4546.8535.1632.9227.394.179.49
Total Debt3.90-----9.821.90
Net Cash / Debt20.2930.4546.8535.1632.9227.39-5.657.59
Assets35.0132.8750.1937.6235.8630.059.6813.21
Liabilities19.4627.3319.0018.115.194.4722.705.54
Book Value15.545.5431.1919.5130.6825.58-52.91-32.23
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name ContraFect Corporation
Country United States
Employees 24
CEO Roger J. Pomerantz

Stock Information

Ticker Symbol CFRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CFRX
IPO Date July 29, 2014

Description

ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin, which has completed Phase II clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic influenza infections. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting gram-negative pathogens; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.